Le Lézard
Classified in: Covid-19 virus
Subject: ATY

Class Action Filed Against Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (KIND) - April 29, 2024 Deadline to Join - Contact Levi & Korsinsky


NEW YORK, March 27, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ("Nextdoor Holdings" or the "Company") (NYSE: KIND) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nextdoor Holdings investors who were adversely affected by alleged securities fraud between July 6, 2021 and November 8, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/nextdoor-holdings-inc-f-k-a-khosla-ventures-acquisition-co-ii-lawsuit-submission-form?prid=72798&wire=4

KIND investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) Nextdoor's financial results prior to the November 2021 merger with Khosla Ventures Acquisition Co. II, had been temporarily inflated by the ephemeral effects of the COVID-19 pandemic, which had pulled forward demand for Nextdoor's platform and cannibalized future advertising revenue growth; (b) rather than being sustained, such growth trends had already begun reversing at the start of the class period; (c) Nextdoor's total addressable market was materially smaller than the 312 million households represented to investors; (d) by the start of the class period, Nextdoor's most important market ? the U.S. market ? was already substantially saturated, impairing the Company's ability to monetize users and increase its average revenue per weekly active user, or U.S. weekly active user metrics; (e) as a result of (a)-(d) above, Nextdoor's revenue guidance for fiscal year 2022 had no reasonable basis in fact and the Company was tracking tens of millions of dollars below the revenue trajectory provided to investors.

WHAT'S NEXT? If you suffered a loss in Nextdoor Holdings during the relevant time frame, you have until April 29, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP


These press releases may also interest you

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference ? May 14-15, 2024 Type: Fireside Chat Presentation Date/Time: May 14,...

at 07:30
New Pacific Metals Corp. ("New Pacific" or the "Company") is pleased to announce the positive results of its metallurgical test program for its Silver Sand project ("Silver Sand") located in Potosi Department, Bolivia. The test program was...

at 07:30
Guanajuato Silver Company Ltd. (the "Company" or "GSilver") is pleased to announce an upsizing of its previously announced brokered, best-efforts offering ("Offering") for an additional C$2,250,000 under a private...

at 07:05
Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter...

at 07:05
Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...

at 07:00
Advancements with Ted Danson is excited to announce an upcoming episode, scheduled to broadcast on Saturday, May 4, 2024, at 8:00 pm ET on Bloomberg. Learn about some of the rising environmental issues, construction costs, and profit margins...



News published on and distributed by: